3-aminocyclopentanecarboxamides as chemokine receptor agonists

Abstract

There is provided a compound of Formula I(a) or I(b) or a pharmaceutically acceptable salt thereof, wherein the various substituents are defined herein.

1. 1,5-anhydro-2,3-dideoxy-3-{[(1R,3S)-3-isopropyl-3-({(1S,4S)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}carbonyl)cyclopentyl]amino}-4-O-methyl-D-erythro-pentitol. 
     
     
       2. A compound of formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
       3. A pharmaceutical composition comprising a compound of  claim 2 , or a pharmaceutically acceptable salt thereof, and a carrier. 
     
     
       4. A method of treating a disease associated with expression or activity of a chemokine receptor in a patient comprising administering to said patient a compound of  claim 2 , or a pharmaceutically acceptable salt thereof, wherein the disease is diabetic nephropathy.